Plasma ω-3 and ω-6 PUFA Concentrations and Risk of Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis.
arachidonic acid
atrial fibrillation
cardiovascular disease
fatty acids
primary prevention
Journal
The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
17
09
2020
revised:
13
11
2020
accepted:
19
01
2021
pubmed:
12
3
2021
medline:
11
1
2022
entrez:
11
3
2021
Statut:
ppublish
Résumé
Current literature examining the prospective relation of circulating omega-3 (n-3) and omega-6 (n-6) PUFAs and atrial fibrillation (AF) is limited to predominantly white populations. We investigated the association of circulating n-3 and n-6 PUFAs with incident AF in participants from the Multi-Ethnic Study of Atherosclerosis. A total of 6229 participants (mean age = 62 y; 53% female; 39% white, 27% black, 22% Hispanic, and 12% Chinese) who were free of baseline AF and with plasma phospholipid PUFAs measured at baseline using GC were prospectively followed for the development of AF. Incident AF was ascertained using International Classification of Diseases-9 codes from hospital discharge records and Medicare claims data with follow-up through 2014. Multivariable Cox proportional hazards regression analysis was performed to determine the risk of incident AF. During a median follow-up of 12.9 y, 813 (13%) participants developed AF. Each higher SD increment in arachidonic acid (AA; 20:4n-6) concentrations was associated with an 11% decreased risk of incident AF (HR: 0.89; 95% CI: 0.82, 0.96). Similarly, higher overall n-6 PUFA concentrations were also associated with a reduced AF risk (HR per SD increment: 0.93; 95% CI: 0.87, 1.00). Although no significant overall associations were observed for any individual n-3 PUFAs, higher circulating concentrations of DHA (22:6n-3) and EPA (20:5n-3) were associated with a decreased AF risk in blacks and Hispanics (DHA only) but not whites or Chinese Americans. In a multiethnic cohort of individuals free of baseline cardiovascular disease, higher plasma concentrations of n-6 PUFAs, particularly AA, were associated with a reduced risk of incident AF. Important differences in AF risk were also noted across race/ethnicity for the n-3 PUFAs DHA and EPA.
Sections du résumé
BACKGROUND
Current literature examining the prospective relation of circulating omega-3 (n-3) and omega-6 (n-6) PUFAs and atrial fibrillation (AF) is limited to predominantly white populations.
OBJECTIVES
We investigated the association of circulating n-3 and n-6 PUFAs with incident AF in participants from the Multi-Ethnic Study of Atherosclerosis.
METHODS
A total of 6229 participants (mean age = 62 y; 53% female; 39% white, 27% black, 22% Hispanic, and 12% Chinese) who were free of baseline AF and with plasma phospholipid PUFAs measured at baseline using GC were prospectively followed for the development of AF. Incident AF was ascertained using International Classification of Diseases-9 codes from hospital discharge records and Medicare claims data with follow-up through 2014. Multivariable Cox proportional hazards regression analysis was performed to determine the risk of incident AF.
RESULTS
During a median follow-up of 12.9 y, 813 (13%) participants developed AF. Each higher SD increment in arachidonic acid (AA; 20:4n-6) concentrations was associated with an 11% decreased risk of incident AF (HR: 0.89; 95% CI: 0.82, 0.96). Similarly, higher overall n-6 PUFA concentrations were also associated with a reduced AF risk (HR per SD increment: 0.93; 95% CI: 0.87, 1.00). Although no significant overall associations were observed for any individual n-3 PUFAs, higher circulating concentrations of DHA (22:6n-3) and EPA (20:5n-3) were associated with a decreased AF risk in blacks and Hispanics (DHA only) but not whites or Chinese Americans.
CONCLUSIONS
In a multiethnic cohort of individuals free of baseline cardiovascular disease, higher plasma concentrations of n-6 PUFAs, particularly AA, were associated with a reduced risk of incident AF. Important differences in AF risk were also noted across race/ethnicity for the n-3 PUFAs DHA and EPA.
Identifiants
pubmed: 33693794
pii: S0022-3166(22)00196-1
doi: 10.1093/jn/nxab016
pmc: PMC8243886
doi:
Substances chimiques
Fatty Acids, Omega-3
0
Fatty Acids, Omega-6
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1479-1486Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL127659
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001420
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.
Références
Clin Chem. 2006 Dec;52(12):2265-72
pubmed: 17053155
Circulation. 2012 Mar 6;125(9):1084-93
pubmed: 22282329
Am J Clin Nutr. 2007 Jul;86(1):74-81
pubmed: 17616765
PLoS Genet. 2011 Jul;7(7):e1002193
pubmed: 21829377
Am J Epidemiol. 2002 Nov 1;156(9):871-81
pubmed: 12397006
Expert Rev Cardiovasc Ther. 2007 Jul;5(4):707-14
pubmed: 17605649
Circulation. 2011 Apr 12;123(14):1501-8
pubmed: 21444879
J Lipid Res. 2005 Feb;46(2):269-80
pubmed: 15576848
Am J Clin Nutr. 1994 Feb;59(2):364-70
pubmed: 8310986
J Diabetes Metab Disord. 2012 Dec 10;11(1):25
pubmed: 23497599
BMJ. 2016 Sep 06;354:i4482
pubmed: 27599725
Circulation. 2011 Feb 15;123(6):584-93
pubmed: 21282499
Hypertension. 2008 Aug;52(2):408-14
pubmed: 18606902
Ann Epidemiol. 2015 Feb;25(2):71-6, 76.e1
pubmed: 25523897
Ann Nutr Metab. 1999;43(2):127-30
pubmed: 10436312
Eur J Clin Nutr. 2008 Oct;62(10):1155-61
pubmed: 17622261
Eur Heart J. 2013 Sep;34(35):2746-51
pubmed: 23900699
BMJ. 2016 Apr 12;353:i1246
pubmed: 27071971
Circulation. 2010 Nov 23;122(21):2110-2
pubmed: 21060074
Clin Sci (Lond). 2003 Jul;105(1):13-20
pubmed: 12589702
Nutrients. 2019 Jul 19;11(7):
pubmed: 31331006
J Am Coll Cardiol. 2011 Feb 15;57(7):870-9
pubmed: 21215550
Exp Biol Med (Maywood). 2010 Jul;235(7):785-95
pubmed: 20558833
PLoS One. 2017 Dec 22;12(12):e0190262
pubmed: 29272310
Prostaglandins Leukot Essent Fatty Acids. 2018 Oct;137:26-38
pubmed: 30293594
PLoS One. 2012;7(5):e36686
pubmed: 22570739
Circulation. 2006 Jul 11;114(2):119-25
pubmed: 16818816
Physiol Res. 2008;57 Suppl 1:S57-S65
pubmed: 18271691
J Natl Med Assoc. 2008 Feb;100(2):237-45
pubmed: 18300541
Cardiovasc Res. 2009 Feb 1;81(2):319-27
pubmed: 19015135
Curr Med Chem. 2007;14(19):2070-80
pubmed: 17691948
Circulation. 2009 Dec 8;120(23):2315-21
pubmed: 19933935
Biochimie. 2009 Jun;91(6):791-5
pubmed: 19455748
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
J Am Heart Assoc. 2013 Dec 18;2(6):e000506
pubmed: 24351702
Diabetes. 2014 Jul;63(7):2356-68
pubmed: 24550191
Circulation. 2019 May 21;139(21):2422-2436
pubmed: 30971107
Prostaglandins Leukot Essent Fatty Acids. 1991 Oct;44(2):127-31
pubmed: 1745654
Am J Clin Nutr. 2012 May;95(5):1003-12
pubmed: 22492369
Br J Pharmacol. 2019 Apr;176(8):1038-1050
pubmed: 29468666
Nutrients. 2019 Mar 06;11(3):
pubmed: 30845776
Eur J Clin Nutr. 2012 May;66(5):600-5
pubmed: 22215136